Best Peptides for Anti-Aging — Evidence Review
"Anti-aging" is the broadest peptide-marketing category and the one with the largest gap between claims and evidence. This guide reviews the peptides with documented age-related effects in specific…
"Anti-aging" is the broadest peptide-marketing category and the one with the largest gap between claims and evidence. This guide reviews the peptides with documented age-related effects in specific domains (skin, GH replacement, mitochondrial function) and is honest about the longevity claims that lack human data.
Peptides with documented age-relevant evidence
GHK-Cu (Copper Tripeptide-1) — skin specifically
The most-studied anti-aging peptide topically. Multiple human studies on reduced wrinkle depth, improved elasticity, and skin-smoothing effects with topical application. Mechanism includes copper-mediated growth-factor signaling.
Important constraint: GHK-Cu evidence is strongest topically for skin. Injectable use for systemic anti-aging effects has weaker support.
Sermorelin — adult GH deficiency
GHRH analog used clinically for adult growth hormone deficiency. Reasonable case for use in age-related GH decline where labs document deficiency. Lower magnitude effect than direct GH replacement; safer profile.
The evidence base is for clinically diagnosed deficiency, not for healthy adults seeking general "longevity" benefit. The latter case is poorly supported.
MOTS-c — mitochondrial function
Mitochondrial-derived peptide with insulin-sensitizing and AMPK-activating action in animal models. Plasma levels decline with age. Synthetic analog (MB-4343) cleared a Phase 1 safety study. Human longevity-outcome data does not yet exist; the case is mechanistic.
Tesamorelin — visceral adipose
Reduces visceral adipose tissue, which is metabolically active and inflammatory. Visceral-fat reduction is a meaningful longevity-relevant outcome — but tesamorelin's evidence is from HIV-associated lipodystrophy populations, not general aging.
Claims that outpace evidence
Epitalon
The Khavinson-program longevity-research peptide with the largest gap between published volume and Western verification. Multiple Russian-program studies report telomerase induction, mortality-reduction in elderly cohorts, and gene-regulatory effects. Independent Western replication is essentially absent. The trial designs do not meet modern blinding and central-randomization standards.
We mention epitalon because it dominates anti-aging community discussion. The evidence does not match the marketing claims.
FOXO4-DRI
The senolytic peptide that became famous from a single 2017 mouse paper showing rejuvenation imagery. Zero human clinical trials. The mouse data is interesting but has not progressed to human safety or efficacy testing in the years since.
1
Humanin and SS-31
Mitochondrial peptides with research interest. Human longevity data does not yet exist.
What the evidence does not support
- Any peptide as a "lifespan extender" in humans (no peptide has demonstrated this in any controlled human trial)
- Epitalon as having Western-replicated gene-regulatory effects
- FOXO4-DRI as having human safety data
- "Anti-aging stacks" combining 4–5 injectable peptides without controlled-trial support
- Use as substitute for the interventions that DO have aging-relevant evidence: caloric balance, resistance training, sleep, blood-pressure control, lipid management, smoking cessation
Practical considerations
The anti-aging peptide space has the worst signal-to-noise ratio of any application area. The strongest aging-relevant evidence in medicine generally is unrelated to peptides — exercise, nutrition, blood pressure control, blood lipid management, sleep, social engagement. Peptide use should not displace these.
Where to source
- GHK-Cu vendor rankings — 14 ranked vendors (topical formulations; cosmetic-grade quality varies)
- Sermorelin vendor rankings — limited
- MOTS-c vendor rankings — limited; lower independent testing volume
- Tesamorelin vendor rankings — regulatorily constrained
Epitalon and FOXO4-DRI have minimal independent third-party testing data; vendor selection here is mostly an act of faith.
What we don't know
- Whether any peptide produces lifespan extension in any controlled human study (the answer to date is "no peptide has been tested for this")
- Whether MOTS-c will mature beyond mitochondrial-research curiosity
- Whether tesamorelin's visceral-fat selectivity has long-term mortality implications outside HIV populations
- Almost everything else in this space
Methodology
Read the full methodology.
This page is educational. The "best peptides for anti-aging" framing reflects what the market discusses, not what the evidence supports. Set expectations accordingly.